Home  >  MEDTECH  > PositiveID Corporation to present M-BAND at ASM Biodefense ...
  >  MEDTECH
Feb 22nd, 2012
 
PositiveID Corporation to present M-BAND at ASM Biodefense and Emerging Diseases Research Meeting
 
The Boeing Company, Hamilton Sundstrand and MicroFluidic Systems to jointly exhibit M-BAND at 10th annual American Society for Microbiology conference.
Send to a friend

PositiveID Corporation's ("PositiveID") (OTCBB:PSID) subsidiary MicroFluidic Systems ("MFS"), a developer of molecular diagnostic systems, announced it will present its M-BAND (Microfluidics-based Bioagent Autonomous Networked Detector) system at the 10th Annual American Society for Microbiology ("ASM") Biodefense and Emerging Diseases Research Meeting, to be held February 26-29, 2012, in Washington, DC at the Omni Shoreham Hotel. PositiveID will jointly exhibit M-BAND with The Boeing Company and Hamilton Sundstrand.

M-BAND, developed under contract for the Department of Homeland Security by MFS, is an early warning system designed to detect the intentional release of aerosolized biological agents. It runs autonomously for up to 30 days, continuously analyzing air samples, typically in high-traffic areas, for the detection of bacteria, viruses, and toxins with results in as little as three hours. Results from individual M-BAND instruments are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments in aggregate. Designed with a high level of operational flexibility, M-BAND can be remotely set to detect for DNA-based pathogens alone, with or without either RNA-based organisms or toxins, or for all three types of pathogens simultaneously at remotely programmable intervals.

According to the ASM, approximately 1,000 leaders and decision makers in the field of biodefense will participate in the Biodefense and Emerging Diseases conference to discuss the critical research necessary to defend against the growing threat of bioterrorism and shape the future of the biodefense research agenda.

About PositiveID Corporation
PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.


 
More MEDTECH news

May 21st
May 15th
May 10th
May 9th
May 9th
 
©2007 Yole Developpement All rights reserved                  Disclaimer | Legal notice | To advertise
Yole Développement: Le Quartz, 75 cours Emile Zola, 69100 Villeurbanne, France. TEL: (33) 472 83 01 80 FAX: (33) 472 83 01 83 E-Mail: info @yole.fr